Hib-DTaP-Hepatitis-B-Poliovirus-vaccine - Merck

Drug Profile

Hib-DTaP-Hepatitis-B-Poliovirus-vaccine - Merck

Alternative Names: DTaP5-HepB-Polio-Hib - Merck; DTP-HepB-Polio-Hib vaccine - Merck; Pediatric hexavalent vaccine; Pediatric hexavalent vaccine PR5i; PR5I; V419; Vaxelis

Latest Information Update: 17 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co; sanofi pasteur
  • Developer Merck & Co; Sanofi Pasteur
  • Class Haemophilus vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 21 Mar 2016 Phase-III clinical trials in Tetanus, Pertussis, Poliomyelitis, Hepatitis B, Haemophilus infections and Diphtheria (In children, Prevention) in Finland (IM) (EudraCT2016-000274-37)
  • 26 Feb 2016 Merck has patents pending for Hib-DTaP-Hepatitis-B-Poliovirus-vaccine in USA (Merck & Co 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top